Blue Steens in May 2020

Catch up on Blue Steens articles and venture further

This month on Blue Steens

Stop COVID-19 hackathon

Hackathons aren’t necessarily just for coders. I’d encourage anyone to contribute to such events. You can be sure to walk away enriched at the end. Read about my most recent experience at a global COVID-19-themed hackathon.

Read >>


Beyond Blue Steens

Coronavirus

⊳ Testing

For quick explanations of the difference between genetic (PCR) and antibody (serological) tests, check out March’s & April’s COVID-19 Testing sections.

⊳ Treatment

  • Remdesivir:

  • (Hydroxy-) Chloroquine:

  • Passive immunisation:

    Passive immunisation involves administering protective antibodies to the patient (essentially what breast milk does for a baby). Plasma therapy is one option (more details in April newsletter), purified or lab-produced antibodies are other ways. In principle, this approach can be applied prophylactically (vaccination) or as treatment.

  • Abivax phase 2b/3 trial approved in Germany. First-in-class small molecule treatment with anti-viral and anti-inflammatory effects. > 1000 elderly & high-risk patients, trial start late May. (Other trials for treatment of HIV and some inflammatory diseases.) [German]

  • Triple therapy with interferon beta-1b, lopinavir-ritonavir and ribavirin (phase 2 trial) may reduce period of viral shedding and, thus, reduce viral load in patient and contagiousness.

  • Glenmark Pharmaceuticals’ anti-viral favipiravir (Avigan) to be trialled in India & Japan to ship Avigan to 43 countries for further trials. Phase 2 & 3 trials already ongoing in some countries.

  • Synairgen’s Interferon beta to prevent harmful lung damage trialled in UK

  • 🏴󠁧󠁢󠁳󠁣󠁴󠁿 Scottish Pneumagen’s drug works by preventing the entry of viruses into lung cells. Hence, it may be of benefit against an array of airway viruses.

⊳ Vaccination

⊳ Other news

Biotech

Out and about


Connect on Twitter, LinkedIn or YouTube if you like.


In this newsletter I share personal views and observations only. For more information and the privacy policy visit Blue Steens.